On this page

fluocinolone acetonide

Prescription ANDA TE AT RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
fluocinolone acetonide
Generic name
fluocinolone acetonide
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Cosette Pharmaceuticals, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
4
Packages
8
Data completeness
77% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Fluocinolone Acetonide .1 mg/g 1191310 View
Fluocinolone Acetonide .25 mg/g 1191310 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
12

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
012787
Application type
ANDA · Abbreviated New Drug Application
Approval date
February 15, 1963
Sponsor
EUROFARMA
Products on application
3
Submissions recorded
40
Products approved under application 012787.
Product Trade name Form Strength Ingredient Status TE Flags
012787-002 SYNALAR CREAM FLUOCINOLONE ACETONIDE Prescription AT RLD RS
012787-004 SYNALAR CREAM FLUOCINOLONE ACETONIDE Prescription AT RLD RS
012787-005 SYNALAR CREAM FLUOCINOLONE ACETONIDE Prescription AT RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 012787.
Type No. Action Status Date Review
Supplement 71 Manufacturing (CMC) Approved March 28, 2013 Priority
Supplement 66 Manufacturing (CMC) Approved September 26, 2000 Priority
Supplement 65 Manufacturing (CMC) Approved July 22, 1996 Priority
Supplement 61 Labeling Approved March 6, 1995 —
Supplement 60 Labeling Approved March 6, 1995 —
Supplement 64 Labeling Approved March 1, 1995 Standard
Supplement 63 Manufacturing (CMC) Approved November 13, 1992 Priority
Supplement 62 Manufacturing (CMC) Approved April 24, 1992 Priority
Supplement 59 Manufacturing (CMC) Approved February 13, 1990 Priority
Supplement 56 Manufacturing (CMC) Approved April 12, 1989 Priority
Supplement 58 Manufacturing (CMC) Approved April 4, 1989 Priority
Supplement 57 Manufacturing (CMC) Approved February 10, 1989 Priority
Supplement 55 Manufacturing (CMC) Approved December 20, 1984 Priority
Supplement 54 Manufacturing (CMC) Approved August 29, 1984 Priority
Supplement 53 Manufacturing (CMC) Approved September 7, 1983 Priority
Supplement 52 Labeling Approved April 8, 1983 —
Supplement 50 Manufacturing (CMC) Approved November 19, 1982 Priority
Supplement 49 Manufacturing (CMC) Approved November 20, 1981 Priority
Supplement 48 Manufacturing (CMC) Approved November 12, 1981 Priority
Supplement 43 Manufacturing (CMC) Approved June 26, 1981 Priority
Supplement 47 Manufacturing (CMC) Approved January 19, 1981 Priority
Supplement 46 Manufacturing (CMC) Approved January 19, 1981 Priority
Supplement 45 Manufacturing (CMC) Approved January 19, 1981 Priority
Supplement 44 Manufacturing (CMC) Approved January 19, 1981 Priority
Supplement 42 Manufacturing (CMC) Approved July 30, 1980 Priority
Supplement 40 Labeling Approved February 19, 1980 —
Supplement 39 Labeling Approved February 19, 1980 —
Supplement 38 Manufacturing (CMC) Approved October 23, 1979 Priority
Supplement 37 Manufacturing (CMC) Approved August 13, 1979 Priority
Supplement 36 Manufacturing (CMC) Approved July 25, 1979 Priority
Supplement 34 Manufacturing (CMC) Approved April 13, 1979 Priority
Supplement 31 Labeling Approved January 10, 1979 —
Supplement 33 Manufacturing (CMC) Approved November 28, 1978 Priority
Supplement 32 Labeling Approved September 12, 1978 —
Supplement 30 Manufacturing (CMC) Approved June 4, 1977 Priority
Supplement 29 Labeling Approved January 4, 1977 —
Supplement 28 Labeling Approved July 8, 1976 —
Supplement 27 Labeling Approved December 12, 1975 —
Supplement 26 Labeling Approved June 26, 1975 —
Original application 1 Type 1 - New Molecular Entity Approved February 15, 1963 Priority

Review documents

  • 0 · Supplement · April 9, 2013
  • 0 · Supplement · April 1, 2013

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20231122). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20231122 HUMAN PRESCRIPTION DRUG · 20221116

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Fluocinolone Acetonide Cream, USP is indicated for the relief of the inflammatory and pruritic mani­festations of corticosteriod-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Fluocinolone Acetonide Cream, USP is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exer­cised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning, Itching, Irritation, Dryness, Folliculitis, Hypertrichosis, Acneiform eruptions, Hypopigmentation, Perioral dermatitis, Allergic contact dermatitis, Maceration of the skin, Secondary infection, Skin atrophy, Striae and Miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Description

openFDA Drug Labeling

DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. Fluocinolone Acetonide is included in this class of synthetic corticosteroids. Chemically Fluocinolone Acetonide is Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6α, 11β, 6α)-), with the molecular formula C 24 H 30 F 2 0 6 , a molecular weight of 452.49 and the following structural formula: Each gram of Fluocinolone Acetonide Cream, USP 0.01% contains 0.1 mg fluocinolone acetonide USP in a water washable cream base consisting of mineral oil (and) lanolin alcohols, isopropyl palmitate NF, propylene glycol stearate, cetyl alcohol NF, sorbitan monostearate NF, polysorbate 60 NF, sorbic acid NF, polyoxyl (40) stearate NF, purified water USP, propylene glycol USP with propylparaben NF and methylparaben NF as preservatives. Each gram of Fluocinolone Acetonide Ointment, USP 0.025% contains 0.25 mg of fluocinolone acetonide USP in an ointment base consisting of light mineral oil NF and white petrolatum USP. Chemical Structure

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Fluocinolone Acetonide Cream, USP 0.01% is supplied in: 15 g tubes NDC 0713-0223-15, and 60 g tubes NDC 0713-0223-60 Fluocinolone Acetonide Ointment, USP 0.025% USP is supplied in: 15 g tubes NDC 0713-0224-15, and 60 g tubes NDC 0713-0224-60 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 VC7669 Rev. 09/2022 8-FLUOCPLNC3

Adverse event reports

Source: openFDA FAERS
4,305
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: FLUOCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class III January 8, 2014 G & W Laboratories Inc Failed Content Uniformity Specifications; at the 18 month time point. Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
62559-288-15 62559-288 ANI Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (62559-288-15) / 15 g in 1 TUBE May 8, 2024
62559-288-60 62559-288 ANI Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (62559-288-60) / 60 g in 1 TUBE May 8, 2024
62559-289-15 62559-289 ANI Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (62559-289-15) / 15 g in 1 TUBE May 8, 2024
62559-289-60 62559-289 ANI Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (62559-289-60) / 60 g in 1 TUBE May 8, 2024
0713-0223-15 0713-0223 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0223-15) / 15 g in 1 TUBE July 26, 1988
0713-0223-60 0713-0223 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0223-60) / 60 g in 1 TUBE July 26, 1988
0713-0709-15 0713-0709 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0709-15) / 15 g in 1 TUBE November 5, 2018
0713-0709-60 0713-0709 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0709-60) / 60 g in 1 TUBE November 5, 2018
62559-288 62559-288 ANI Pharmaceuticals, Inc. — May 8, 2024
62559-289 62559-289 ANI Pharmaceuticals, Inc. — May 8, 2024
0713-0223 0713-0223 Cosette Pharmaceuticals, Inc. — July 26, 1988
0713-0709 0713-0709 Cosette Pharmaceuticals, Inc. — November 5, 2018

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.